On April 21, 2026, Inhibrx Biosciences announced interim results from its clinical study of ozekibart for colorectal cancer, showing a 20% objective response rate and a median progression-free survival of 5.5 months in heavily pretreated patients. The company is planning future discussions with the FDA regarding treatment pathways and has submitted a Biologics License Application for another indication.